Previous 10 | Next 10 |
Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA - ( NewMediaWire ) - May 15, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...
2023-05-11 14:12:03 ET Following a meeting of its expert advisors, the World Health Organization announced Thursday that the monkeypox outbreak would no longer be regarded as a public health emergency of international concern (PHEIC). Monkeypox virus, currently known as mpox, led to a g...
ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ V...
2023-05-07 11:25:04 ET GeoVax Labs, Inc. (GOVX) Q1 2023 Earnings Conference Call May 4, 2023 16:30 ET Company Participants Gabby DeGravina - Investor Relations David Dodd - Chairman and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newm...
2023-05-04 16:55:41 ET GeoVax press release ( NASDAQ: GOVX ): Q1 GAAP EPS of -$0.15 beats by $0.08 . GeoVax reported cash balances of $23,849,860 at March 31, 2023, as compared to $27,612,732 at December 31, 2022, a decrease of $3,762,872. For further details see...
Cancer Gene Therapy Program and Next-Generation COVID-19 Vaccine Advancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30 p.m. ET ATLANTA, GA - ( NewMediaWire ) - May 04, 2023 - GeoVax Labs, Inc. (Nas...
ATLANTA, GA - ( NewMediaWire ) - April 26, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on Infectious Diseases in the ...
ATLANTA, GA - ( NewMediaWire ) - April 25, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial results on Thursday, May 4, 2...
Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infec...
Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA - ( NewMediaWire ) - April 06, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines ...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...